| Baseline resistance profile | New cases | Previously treated cases | ||
| With each resistance profile | Diagnosed with MDR-TB during treatment | With each resistance profile | Diagnosed with MDR-TB during treatment | |
| None detected | 2114 | 76 (3.6) | 413 | 46 (11.1) |
| H-mono | 107 | 11 (10.3) | 40 | 1 (2.5) |
| R-mono | 26 | 2 (7.7) | 12 | 6 (50.0) |
| E-mono | 25 | 3 (12.0) | 3 | 0 (0.0) |
| S-mono | 250 | 13 (5.2) | 57 | 2 (3.5) |
| H+E | 11 | 2 (18.2) | 2 | 2 (100.0) |
| H+S | 149 | 17 (11.4) | 68 | 17 (25.0) |
| R+E | 2 | 0 (0.0) | 3 | 1 (33.3) |
| R+S | 10 | 1 (10.0) | 6 | 5 (83.3) |
| E+S | 6 | 1 (16.7) | 2 | 0 (0.0) |
| H+E+S | 50 | 15 (30.0) | 15 | 7 (46.7) |
| R+E+S | 7 | 4 (57.1) | 4 | 4 (100.0) |
| Any H | 317 | 45 (14.2) | 125 | 27 (21.6) |
| Any R | 45 | 7 (15.6) | 26 | 17 (65.4) |
| Any E | 101 | 25 (24.8) | 30 | 15 (50.0) |
| Any S | 472 | 51 (10.8) | 153 | 36 (23.5) |
| Any resistance | 648 | 69 (10.6) | 213 | 46 (21.6) |
| Any 1 drug | 408 | 29 (7.1) | 112 | 9 (8.0) |
| Any 2 drugs | 178 | 21 (11.8) | 81 | 25 (30.9) |
| Any 3 drugs | 57 | 19 (33.3) | 19 | 11 (57.9) |
| Total | 2762 | 145 (5.2) | 626 | 92 (14.7) |
Data are presented as n or n (%). H: isoniazid; R: rifampicin; E: ethambutol; S: streptomycin. Only 43 cases were tested for resistance to pyrazinamide, all tested negative. #: Between January 1, 2007 and December 31, 2010.